NCT06518538View on ClinicalTrials.gov

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 15, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions
Pancreatic Cancer Stage IV
Interventions
DRUG

CPI-613, modified Folfirinox

"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"

Trial Locations (1)

11206

Hirschfeld Oncology, Brooklyn

Sponsors
All Listed Sponsors
lead

Cornerstone Pharmaceuticals

INDUSTRY

NCT06518538 - Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter